TG Therapeutics | TGTX - Current Assets


TG Therapeutics reported $1.15B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Alaunos Therapeutics USD 970K 1.02M Mar/2026
Amgen USD 34.96B 3.49B Jun/2026
Ardelyx USD 381.87M 447K Mar/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
Bayer EUR 33.64B 1.66B Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
Corcept Therapeutics USD 439.68M 13.64M Jun/2026
Curis USD 16.61M 9.7M Mar/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
J&J USD 59.77B 601M Jun/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Novartis USD 27.35B 744M Jun/2026
Novavax USD 771.1M 79.72M Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
TG Therapeutics USD 1.15B 58.72M Jun/2026
Verastem USD 202.9M 20.51M Mar/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026